Do effects of sodium-glucose cotransporter-2 inhibitors in patients with diabetes give insight into potential use in non-diabetic kidney disease?

Current Opinion in Nephrology and Hypertension

Volumn 26, Issue 5, 2017, Pages 358-367

  Rajasekeran, Harindra ^a,b   Cherney, David Z ^a,b   Lovshin, Julie A ^c  

^a University Health Network   (United States)

^b Department of Physiology ^*  (United States)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

chronic kidney disease; natriuresis; renal hemodynamic function; sodium glucose cotransporter 2 inhibition

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; DIURETIC AGENT; RENIN INHIBITOR; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; SODIUM; SODIUM GLUCOSE COTRANSPORTER 2;

CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DRUG EFFECT; DRUG MECHANISM; FOCAL GLOMERULOSCLEROSIS; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY DISEASE; OBESITY; PRIORITY JOURNAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; BLOOD PRESSURE; DRUG EFFECTS; GLOMERULUS; GLUCOSE BLOOD LEVEL; HEMODYNAMICS; KIDNEY PROXIMAL TUBULE; METABOLISM; NATRIURESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY;

BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HEMODYNAMICS; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY GLOMERULUS; KIDNEY TUBULES, PROXIMAL; NATRIURESIS; RENAL INSUFFICIENCY, CHRONIC; SODIUM; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85020185645     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000343     Document Type: Review

References (59)

1. Mudaliar S, Polidori D, Zambrowicz B, Henry RR. Sodium-glucose cotran-sporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside. Diabetes Care 2015; 38:2344-2353.
2. Zinman B, Wanner C, Lachin JM, et al., EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373:2117-2128.
3. Helal I, Fick-Brosnahan GM, Reed-Gitomer B, Schrier RW. Glomerular hyperfiltration: definitions, mechanisms and clinical implications. Nat Rev Nephrol 2012; 8:293-300.
4. Wanner C, Inzucchi SE, Lachin JM, et al., EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375:323-334.
5. Zingerman B, Herman-Edelstein M, Erman A, et al. Effect of acetazolamide on obesity-induced glomerular hyperfiltration: a randomized controlled trial. PLoS One 2015; 10:e0137163.
6. Liu JJ, Lee T, DeFronzo RA. Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes 2012; 61:2199-2204.
7. Pollock CA, Bostrom TE, Dyne M, et al. Tubular sodium handling and tubuloglomerular feedback in compensatory renal hypertrophy. Pflugers Arch 1992; 420:159-166.
8. Chao EC, Henry RR. SGLT2 inhibition: a novel strategy for diabetes treatment. Nat Rev Drug Discov 2010; 9:551-559.
9. Ferrannini E, Veltkamp SA, Smulders RA, Kadokura T. Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care 2013; 36:1260-1265.
10. Grossman E, Verdecchia P, Shamiss A, et al. Diuretic treatment of hypertension. Diabetes Care 2011; 34 (Suppl 2):S313-S319.
11. Chilton R, Tikkanen I, Cannon CP, et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab 2015; 17:1180-1193.
12. Osorio H, Bautista R, Rios A, et al. Effect of phlorizin on SGLT2 expression in the kidney of diabetic rats. J Nephrol 2010; 23:541-546.
13. Wilding JP, Norwood P, T'joen C, et al. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 2009; 32:1656-1662.
14. Baker WL, Smyth LR, Riche DM, et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 2014; 8:262-275.
15. Lovshin JA, Gilbert RE. Are SGLT2 inhibitors reasonable antihypertensive drugs and renoprotective? Curr Hypertens Rep 2015; 17:551.
16. Gilbert RE. Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering? Kidney Int 2014; 86:693-700.
17. Eddy AA. Proteinuria and interstitial injury. Nephrol Dial Transplant 2004; 19:277-281.
18. Rajasekeran H, Lytvyn Y, Cherney DZ. Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis. Kidney Int 2016; 89:524-526.
19. Fioretto P, Stefansson BV, Johnsson E, et al. Dapagliflozin reduces albumi-nuria over 2 years in patients with type 2 diabetes mellitus and renal impairment. Diabetologia 2016; 59:2036-2039.
20. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013; 15:463-473.
21. Heerspink HJ, Johnsson E, Gause-Nilsson I, et al. Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angio-tensin blockers. Diabetes Obes Metab 2016; 18:590-597.
22. Vallon V, Richter K, Blantz RC, et al. Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol 1999; 10:2569-2576.
23. Schnermann J, Briggs JP. Tubuloglomerular feedback: mechanistic insights from gene-manipulated mice. Kidney Int 2008; 74:418-426.
24. Sun D, Samuelson LC, Yang T, et al. Mediation of tubuloglomerular feedback by adenosine: evidence from mice lacking adenosine 1 receptors. Proc Natl Acad Sci USA 2001; 98:9983-9988.
25. Heerspink HJ, Perkins BA, Fitchett DH, et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 2016; 134:752-772.
26. Heerspink HJ, Desai M, Jardine M, et al. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol 2017; 28:368-375.
27. Cherney D, Lund SS, Perkins BA, et al. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macro-albuminuria in patients with type 2 diabetes. Diabetologia 2016; 59:1860-1870.
28. Sochett EB, Cherney DZ, Curtis JR, et al. Impact of renin angiotensin system modulation on the hyperfiltration state in type 1 diabetes. J Am Soc Nephrol 2006; 17:1703-1709.
29. Cherney DZ, Perkins BA, Soleymanlou N, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol 2014; 13:28.
30. Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014; 129:587-597.
31. Stanton RC. Sodium glucose transport 2 (SGLT2) inhibition decreases glomerular hyperfiltration: is there a role for SGLT2 inhibitors in diabetic kidney disease? Circulation 2014; 129:542-544.
32. Duarte JD, Cooper-DeHoff RM. Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics. Expert Rev Cardiovasc Ther 2010; 8:793-802.
33. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43 (5 Suppl 1):S1-S290.
34. Vogt L, Waanders F, Boomsma F, et al. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008; 19:999-1007.
35. Rahman A, Kittikulsuth W, Fujisawa Y, et al. Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome. J Hypertens 2016; 34:893-906.
36. Devineni D, Vaccaro N, Polidori D, et al. Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. Clin Ther 2014; 36:698-710.
37. Weber MA, Mansfield TA, Cain VA, et al. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol 2016; 4:211-220.
38. Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE). [Cited 30 November 2015]; Web Page for CREDENCE Clinical Trial]. Available from: https://clinicaltrials.gov/ct2/show/NCT02065791?term= NCT02065791&rank=1. [Accessed May 15, 2017]
39. A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus (CANVAS-R). [Cited 30 November 2015]; Web Page for CANVAS-R Clinical trial]. Available from: https://clinicaltrials.gov/ct2/show/record/NCT01989754. [Accessed May 15, 2017]
40. Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI58). [Cited 2017; Webpage for DE-CLARE-TIMI58 Clinical Trial]. Available from: https://clinicaltrials.gov/ct2/show/NCT01730534. [Accessed May 15, 2017]
41. CANVAS-CANagliflozin cardiovascular Assessment Study (CANVAS). [Cited 2017]; Web Page for CANVAS Clinical trial]. Available from: https://clinicaltrials.gov/ct2/show/NCT01032629.
42. Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004). [Cited 2017; Available from: https://clinicaltrials.gov/ct2/show/NCT01986881. [Accessed May 15, 2017]
43. Inzucchi SE, Zinman B, Wanner C, et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res 2015; 12:90-100.
44. Kambham N, Markowitz GS, Valeri AM, et al. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001; 59:1498-1509.
45. Praga M. Synergy of low nephron number and obesity: a new focus on hyperfiltration nephropathy. Nephrol Dial Transplant 2005; 20:2594-2597.
46. Fowler SM, Kon V, Ma L, et al. Obesity-related focal and segmental glomer-ulosclerosis: normalization of proteinuria in an adolescent after bariatric surgery. Pediatr Nephrol 2009; 24:851-855.
47. Kanasaki K, Kitada M, Kanasaki M, et al. The biological consequence of obesity on the kidney. Nephrol Dial Transplant 2013; 28 (Suppl 4):iv1-iv7.
48. Chandra A, Biersmith M, Tolouian R. Obesity and kidney protection. J Nephropathol 2014; 3:91-97.
49. Swaminathan S, Leung N, Lager DJ, et al. Changing incidence of glomerular disease in Olmsted County, Minnesota: a 30-year renal biopsy study. Clin J Am Soc Nephrol 2006; 1:483-487.
50. Korbet SM. Treatment of primary focal segmental glomerulosclerosis. Kidney Int 2002; 62:2301-2310.
51. Lichtnekert J, Kaverina NV, Eng DG, et al. Renin-angiotensin-aldosterone system inhibition increases podocyte derivation from cells of renin lineage. J Am Soc Nephrol 2016; 27:3611-3627.
52. Kojima N, Williams JM, Takahashi T, et al. Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats. J Pharmacol Exp Ther 2013; 345:464-472.
53. Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects (TRANSLATE). [Cited 2016; Web Page for TRANSLATE Clinical Trial]. Available from: https://clinical trials. gov/ct2/show/NCT02585804?term=translate&rank=2. [Accessed May 15, 2017]
54. Magistroni R, D'Agati VD, Appel GB, et al. New developments in the genetics, pathogenesis, and therapy of IgA nephropathy. Kidney Int 2015; 88:974-989.
55. Barratt J, Feehally J. IgA nephropathy. J Am Soc Nephrol 2005; 16:2088-2097.
56. Bartosik LP, Lajoie G, Sugar L, et al. Predicting progression in IgA nephro-pathy. Am J Kidney Dis 2001; 38:728-735.
57. Maschio G, Cagnoli L, Claroni F, et al. ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: a multicentre, randomized, placebo-controlled study. Nephrol Dial Transplant 1994; 9:265-269.
58. Heyman SN, Khamaisi M, Rosen S, et al.Potential hypoxic renal injury in patients with diabetes on SGLT2 inhibitors: caution regarding concomitant use of NSAIDS and iodinated contrast media. Diabetes Care 2017; 40:e40-e41.
59. Watts NB, Bilezikian JP, Usiskin K, et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2016; 101:157-166.